抗糖尿病药物与伊朗老年人骨质疏松症、肌肉疏松症和骨肉疏松症之间的关系;布什尔老年人健康(BEH)计划。

IF 2.5 4区 医学 Q3 PHARMACOLOGY & PHARMACY
DARU Journal of Pharmaceutical Sciences Pub Date : 2024-06-01 Epub Date: 2023-12-22 DOI:10.1007/s40199-023-00497-5
Yasmin Heydarzadeh Sohi, Ali Golestani, Ghodratollah Panahi, Ozra Tabatabaei-Malazy, Kazem Khalagi, Noushin Fahimfar, Afshin Ostovar, Mahnaz Sanjari, Bagher Larijani, Iraj Nabipour
{"title":"抗糖尿病药物与伊朗老年人骨质疏松症、肌肉疏松症和骨肉疏松症之间的关系;布什尔老年人健康(BEH)计划。","authors":"Yasmin Heydarzadeh Sohi, Ali Golestani, Ghodratollah Panahi, Ozra Tabatabaei-Malazy, Kazem Khalagi, Noushin Fahimfar, Afshin Ostovar, Mahnaz Sanjari, Bagher Larijani, Iraj Nabipour","doi":"10.1007/s40199-023-00497-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Various risk factors are mentioned for osteoporosis, sarcopenia, and osteosarcopenia. Our aim is to assess the impacts of anti-diabetic drugs on these disorders.</p><p><strong>Methods: </strong>To perform this study, the participants' data was extracted from the Bushehr Elderly Health (BEH) program in Iran. Afterward, the data were categorized into three subgroups: osteoporosis, sarcopenia, and osteosarcopenia, based on WHO and European Working Group on Sarcopenia in Older People (EWGSOP-2) working group definitions. Demographic characteristics, anthropometric measures, past medical history, and current medications were recorded. Pearson chi-squared and simple/multiple logistic regression using Python (3.11.4) and R (4.3.1) programming software assessed the association between anti-diabetic agents and these bone disorders.</p><p><strong>Results: </strong>Out of 1995 participants, 820, 848, and 404 had osteoporosis, sarcopenia, or osteosarcopenia, respectively. Among all types of anti-diabetic drugs, a significant protective association between osteoporosis and consumption of second-generation sulfonylureas was found; Adjusted Odd Ratio (AOR) = 0.65 ([95% CI: 0.45-0.94], p-value = 0.023). No associations were found between sarcopenia and consumption of anti-diabetic agents. A significant association was observed between using Meglitinides and the risk of osteosarcopenia; AOR = 4.98 ([95% CI: 1.5-16.55], p-value = 0.009).</p><p><strong>Conclusion: </strong>In conclusion, a protective association between consumption of second-generation sulfonylureas and osteoporosis was found. Moreover, a positive association was found between the consumption of meglitinides and osteosarcopenia. However, to support these findings, further studies are recommended.</p>","PeriodicalId":10888,"journal":{"name":"DARU Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087384/pdf/","citationCount":"0","resultStr":"{\"title\":\"The association between anti-diabetic agents and osteoporosis, sarcopenia, and osteosarcopenia among Iranian older adults; Bushehr Elderly Health (BEH) program.\",\"authors\":\"Yasmin Heydarzadeh Sohi, Ali Golestani, Ghodratollah Panahi, Ozra Tabatabaei-Malazy, Kazem Khalagi, Noushin Fahimfar, Afshin Ostovar, Mahnaz Sanjari, Bagher Larijani, Iraj Nabipour\",\"doi\":\"10.1007/s40199-023-00497-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Various risk factors are mentioned for osteoporosis, sarcopenia, and osteosarcopenia. Our aim is to assess the impacts of anti-diabetic drugs on these disorders.</p><p><strong>Methods: </strong>To perform this study, the participants' data was extracted from the Bushehr Elderly Health (BEH) program in Iran. Afterward, the data were categorized into three subgroups: osteoporosis, sarcopenia, and osteosarcopenia, based on WHO and European Working Group on Sarcopenia in Older People (EWGSOP-2) working group definitions. Demographic characteristics, anthropometric measures, past medical history, and current medications were recorded. Pearson chi-squared and simple/multiple logistic regression using Python (3.11.4) and R (4.3.1) programming software assessed the association between anti-diabetic agents and these bone disorders.</p><p><strong>Results: </strong>Out of 1995 participants, 820, 848, and 404 had osteoporosis, sarcopenia, or osteosarcopenia, respectively. Among all types of anti-diabetic drugs, a significant protective association between osteoporosis and consumption of second-generation sulfonylureas was found; Adjusted Odd Ratio (AOR) = 0.65 ([95% CI: 0.45-0.94], p-value = 0.023). No associations were found between sarcopenia and consumption of anti-diabetic agents. A significant association was observed between using Meglitinides and the risk of osteosarcopenia; AOR = 4.98 ([95% CI: 1.5-16.55], p-value = 0.009).</p><p><strong>Conclusion: </strong>In conclusion, a protective association between consumption of second-generation sulfonylureas and osteoporosis was found. Moreover, a positive association was found between the consumption of meglitinides and osteosarcopenia. However, to support these findings, further studies are recommended.</p>\",\"PeriodicalId\":10888,\"journal\":{\"name\":\"DARU Journal of Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087384/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"DARU Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40199-023-00497-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"DARU Journal of Pharmaceutical Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40199-023-00497-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:骨质疏松症、肌肉疏松症和骨关节疏松症的风险因素多种多样。我们的目的是评估抗糖尿病药物对这些疾病的影响:为了开展这项研究,我们从伊朗布什尔老年人健康(BEH)项目中提取了参与者的数据。然后,根据世界卫生组织和欧洲老年人肌肉疏松症工作组(EWGSOP-2)的定义,将数据分为三个亚组:骨质疏松症、肌肉疏松症和骨肉疏松症。研究人员还记录了人口统计学特征、人体测量指标、既往病史和当前用药情况。使用 Python (3.11.4) 和 R (4.3.1) 编程软件进行皮尔逊卡方和简单/多重逻辑回归,以评估抗糖尿病药物与这些骨骼疾病之间的关联:在 1995 名参与者中,分别有 820 人、848 人和 404 人患有骨质疏松症、肌肉疏松症或骨肌疏松症。在所有类型的抗糖尿病药物中,骨质疏松症与服用第二代磺脲类药物之间存在明显的保护性关联;调整后奇数比(AOR)= 0.65([95% CI:0.45-0.94],P 值= 0.023)。没有发现肌肉疏松症与服用抗糖尿病药物有关。使用甲格列汀类药物与患骨肉疏松症的风险之间存在明显关联;AOR = 4.98([95% CI:1.5-16.55],P 值 = 0.009):总之,研究发现服用第二代磺脲类药物与骨质疏松症之间存在保护性关联。此外,还发现服用甲格列汀类药物与骨质疏松之间存在正相关。不过,为支持这些发现,建议开展进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The association between anti-diabetic agents and osteoporosis, sarcopenia, and osteosarcopenia among Iranian older adults; Bushehr Elderly Health (BEH) program.

The association between anti-diabetic agents and osteoporosis, sarcopenia, and osteosarcopenia among Iranian older adults; Bushehr Elderly Health (BEH) program.

Purpose: Various risk factors are mentioned for osteoporosis, sarcopenia, and osteosarcopenia. Our aim is to assess the impacts of anti-diabetic drugs on these disorders.

Methods: To perform this study, the participants' data was extracted from the Bushehr Elderly Health (BEH) program in Iran. Afterward, the data were categorized into three subgroups: osteoporosis, sarcopenia, and osteosarcopenia, based on WHO and European Working Group on Sarcopenia in Older People (EWGSOP-2) working group definitions. Demographic characteristics, anthropometric measures, past medical history, and current medications were recorded. Pearson chi-squared and simple/multiple logistic regression using Python (3.11.4) and R (4.3.1) programming software assessed the association between anti-diabetic agents and these bone disorders.

Results: Out of 1995 participants, 820, 848, and 404 had osteoporosis, sarcopenia, or osteosarcopenia, respectively. Among all types of anti-diabetic drugs, a significant protective association between osteoporosis and consumption of second-generation sulfonylureas was found; Adjusted Odd Ratio (AOR) = 0.65 ([95% CI: 0.45-0.94], p-value = 0.023). No associations were found between sarcopenia and consumption of anti-diabetic agents. A significant association was observed between using Meglitinides and the risk of osteosarcopenia; AOR = 4.98 ([95% CI: 1.5-16.55], p-value = 0.009).

Conclusion: In conclusion, a protective association between consumption of second-generation sulfonylureas and osteoporosis was found. Moreover, a positive association was found between the consumption of meglitinides and osteosarcopenia. However, to support these findings, further studies are recommended.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
DARU Journal of Pharmaceutical Sciences
DARU Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
期刊介绍: DARU Journal of Pharmaceutical Sciences is a peer-reviewed journal published on behalf of Tehran University of Medical Sciences. The journal encompasses all fields of the pharmaceutical sciences and presents timely research on all areas of drug conception, design, manufacture, classification and assessment. The term DARU is derived from the Persian name meaning drug or medicine. This journal is a unique platform to improve the knowledge of researchers and scientists by publishing novel articles including basic and clinical investigations from members of the global scientific community in the forms of original articles, systematic or narrative reviews, meta-analyses, letters, and short communications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信